JP2012525430A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012525430A5 JP2012525430A5 JP2012508751A JP2012508751A JP2012525430A5 JP 2012525430 A5 JP2012525430 A5 JP 2012525430A5 JP 2012508751 A JP2012508751 A JP 2012508751A JP 2012508751 A JP2012508751 A JP 2012508751A JP 2012525430 A5 JP2012525430 A5 JP 2012525430A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrido
- indol
- dihydro
- methyl
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 101
- 150000003839 salts Chemical class 0.000 claims description 77
- -1 aminocarbonylamino, aminocarbonyloxy, aminosulfonyl Chemical group 0.000 claims description 65
- 125000000217 alkyl group Chemical group 0.000 claims description 60
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 38
- 125000005843 halogen group Chemical group 0.000 claims description 36
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 27
- 125000003545 alkoxy group Chemical group 0.000 claims description 18
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 18
- 239000012453 solvate Substances 0.000 claims description 16
- 102000000543 Histamine Receptors Human genes 0.000 claims description 12
- 108010002059 Histamine Receptors Proteins 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 7
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- ALALGYYKKWHHFT-UHFFFAOYSA-N 1-(2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-2-pyridin-4-ylpropan-2-ol Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC(C)(O)C1=CC=NC=C1 ALALGYYKKWHHFT-UHFFFAOYSA-N 0.000 claims description 4
- NHBJEVLRXOFTHJ-UHFFFAOYSA-N 1-(8-chloro-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-2-(4-fluorophenyl)hexan-2-ol Chemical compound C1=2CCN(C)CC=2C2=CC(Cl)=CC=C2N1CC(O)(CCCC)C1=CC=C(F)C=C1 NHBJEVLRXOFTHJ-UHFFFAOYSA-N 0.000 claims description 4
- PXEPSGXCVODYGD-UHFFFAOYSA-N 2-(2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-ylethanol Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC(O)C1=CC=NC=C1 PXEPSGXCVODYGD-UHFFFAOYSA-N 0.000 claims description 4
- FFPDVUKDLHXYPS-UHFFFAOYSA-N 2-(8-chloro-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-1-pyridin-4-ylethanol Chemical compound C1N(C)CCC2=C1C1=CC(Cl)=CC=C1N2CC(O)C1=CC=NC=C1 FFPDVUKDLHXYPS-UHFFFAOYSA-N 0.000 claims description 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- MXLLWYGJUMMXIK-UHFFFAOYSA-N 1-(2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-2-(4-methoxyphenyl)propan-2-ol Chemical compound C1=CC(OC)=CC=C1C(C)(O)CN1C2=CC=C(C)C=C2C2=C1CCN(C)C2 MXLLWYGJUMMXIK-UHFFFAOYSA-N 0.000 claims description 3
- IRLRNWRMIBNDMJ-UHFFFAOYSA-N 1-(2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-2-pyrazin-2-ylpropan-2-ol Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC(C)(O)C1=CN=CC=N1 IRLRNWRMIBNDMJ-UHFFFAOYSA-N 0.000 claims description 3
- FHGOXDWNWJQYGK-UHFFFAOYSA-N 1-(2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-2-pyrimidin-4-ylpropan-2-ol Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC(C)(O)C1=CC=NC=N1 FHGOXDWNWJQYGK-UHFFFAOYSA-N 0.000 claims description 3
- IDQXHUHLSUEWOD-UHFFFAOYSA-N 1-(2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-2-pyridin-4-ylpropan-2-ol Chemical compound C1N(C)CCC2=C1C1=CC=CC=C1N2CC(C)(O)C1=CC=NC=C1 IDQXHUHLSUEWOD-UHFFFAOYSA-N 0.000 claims description 3
- UYCVKKGODKBIIQ-UHFFFAOYSA-N 1-(7,8-dichloro-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-2-pyridin-4-ylpropan-2-ol Chemical compound C1N(C)CCC2=C1C1=CC(Cl)=C(Cl)C=C1N2CC(C)(O)C1=CC=NC=C1 UYCVKKGODKBIIQ-UHFFFAOYSA-N 0.000 claims description 3
- GPDOQWMVEXTBOT-UHFFFAOYSA-N 1-(8,9-dichloro-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-2-pyridin-4-ylpropan-2-ol Chemical compound C1N(C)CCC2=C1C1=C(Cl)C(Cl)=CC=C1N2CC(C)(O)C1=CC=NC=C1 GPDOQWMVEXTBOT-UHFFFAOYSA-N 0.000 claims description 3
- PTUZCMGIQGFPDX-UHFFFAOYSA-N 1-(8-chloro-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-2-(3-fluoro-4-methoxyphenyl)propan-2-ol Chemical compound C1=C(F)C(OC)=CC=C1C(C)(O)CN1C2=CC=C(Cl)C=C2C2=C1CCN(C)C2 PTUZCMGIQGFPDX-UHFFFAOYSA-N 0.000 claims description 3
- LOLFYIWPYGTMJO-UHFFFAOYSA-N 2-(2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-1-(4-fluorophenyl)ethanol Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC(O)C1=CC=C(F)C=C1 LOLFYIWPYGTMJO-UHFFFAOYSA-N 0.000 claims description 3
- FKAGVDSAIOJBEG-UHFFFAOYSA-N 4-[1-(2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-2-hydroxypropan-2-yl]phenol Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC(C)(O)C1=CC=C(O)C=C1 FKAGVDSAIOJBEG-UHFFFAOYSA-N 0.000 claims description 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 3
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 claims description 3
- IPFQISBRAHCMTC-QFIPXVFZSA-N (2r)-1-(2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-2-pyridin-4-ylbutan-2-ol Chemical compound C1([C@@](O)(CN2C3=CC=C(C)C=C3C=3CN(C)CCC=32)CC)=CC=NC=C1 IPFQISBRAHCMTC-QFIPXVFZSA-N 0.000 claims description 2
- NHBJEVLRXOFTHJ-DEOSSOPVSA-N (2r)-1-(8-chloro-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-2-(4-fluorophenyl)hexan-2-ol Chemical compound C1([C@@](O)(CN2C3=CC=C(Cl)C=C3C=3CN(C)CCC=32)CCCC)=CC=C(F)C=C1 NHBJEVLRXOFTHJ-DEOSSOPVSA-N 0.000 claims description 2
- IPFQISBRAHCMTC-JOCHJYFZSA-N (2s)-1-(2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-2-pyridin-4-ylbutan-2-ol Chemical compound C1([C@](O)(CN2C3=CC=C(C)C=C3C=3CN(C)CCC=32)CC)=CC=NC=C1 IPFQISBRAHCMTC-JOCHJYFZSA-N 0.000 claims description 2
- WMQWGFBKVULIPU-UHFFFAOYSA-N 1-(2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-2-(4-fluorophenyl)butan-2-ol Chemical compound C1=2CCN(C)CC=2C2=CC(C)=CC=C2N1CC(O)(CC)C1=CC=C(F)C=C1 WMQWGFBKVULIPU-UHFFFAOYSA-N 0.000 claims description 2
- IPFQISBRAHCMTC-UHFFFAOYSA-N 1-(2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-2-pyridin-4-ylbutan-2-ol Chemical compound C1=2CCN(C)CC=2C2=CC(C)=CC=C2N1CC(O)(CC)C1=CC=NC=C1 IPFQISBRAHCMTC-UHFFFAOYSA-N 0.000 claims description 2
- IABZWPDEAGALDE-UHFFFAOYSA-N 1-(2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-3-methyl-2-pyridin-4-ylbutan-2-ol Chemical compound C1=2CCN(C)CC=2C2=CC(C)=CC=C2N1CC(O)(C(C)C)C1=CC=NC=C1 IABZWPDEAGALDE-UHFFFAOYSA-N 0.000 claims description 2
- RAYAGSPPADIRJE-UHFFFAOYSA-N 1-(2-cyclopropyl-8-methyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-2-(2-methylpyridin-4-yl)propan-2-ol Chemical compound C1=2CCN(C3CC3)CC=2C2=CC(C)=CC=C2N1CC(C)(O)C1=CC=NC(C)=C1 RAYAGSPPADIRJE-UHFFFAOYSA-N 0.000 claims description 2
- JHNYSIBNEXURAE-UHFFFAOYSA-N 1-(2-ethyl-8-methyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-2-(4-fluorophenyl)propan-2-ol Chemical compound C1N(CC)CCC2=C1C1=CC(C)=CC=C1N2CC(C)(O)C1=CC=C(F)C=C1 JHNYSIBNEXURAE-UHFFFAOYSA-N 0.000 claims description 2
- YJRGOONEJAQERR-UHFFFAOYSA-N 1-(8-chloro-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-3-methyl-2-pyridin-4-ylbutan-2-ol Chemical compound C1=2CCN(C)CC=2C2=CC(Cl)=CC=C2N1CC(O)(C(C)C)C1=CC=NC=C1 YJRGOONEJAQERR-UHFFFAOYSA-N 0.000 claims description 2
- UEORSAWMQSHTKE-UHFFFAOYSA-N 1-[8-methyl-2-(2,2,2-trifluoroethyl)-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl]-2-pyridin-4-ylpropan-2-ol Chemical compound C1=2CCN(CC(F)(F)F)CC=2C2=CC(C)=CC=C2N1CC(C)(O)C1=CC=NC=C1 UEORSAWMQSHTKE-UHFFFAOYSA-N 0.000 claims description 2
- RWJZQZVBGBCVFN-UHFFFAOYSA-N 1-cyclohexyl-2-(2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-1-(4-fluorophenyl)ethanol Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC(O)(C=1C=CC(F)=CC=1)C1CCCCC1 RWJZQZVBGBCVFN-UHFFFAOYSA-N 0.000 claims description 2
- KJZCUPMXUFTZLV-UHFFFAOYSA-N 2,3,8-trimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)C(C)CC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 KJZCUPMXUFTZLV-UHFFFAOYSA-N 0.000 claims description 2
- HMYDVYGSXLBJKK-UHFFFAOYSA-N 2,3,8-trimethyl-5-[2-(6-methylpyridin-3-yl)propyl]-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1=2CC(C)N(C)CC=2C2=CC(C)=CC=C2N1CC(C)C1=CC=C(C)N=C1 HMYDVYGSXLBJKK-UHFFFAOYSA-N 0.000 claims description 2
- VDNUKKJGOKIGOK-UHFFFAOYSA-N 2-(2,4-difluorophenyl)-1-(2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)propan-2-ol Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC(C)(O)C1=CC=C(F)C=C1F VDNUKKJGOKIGOK-UHFFFAOYSA-N 0.000 claims description 2
- NSYXDDRZUMDVIW-UHFFFAOYSA-N 2-(2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-1-(4-fluorophenyl)ethanone Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC(=O)C1=CC=C(F)C=C1 NSYXDDRZUMDVIW-UHFFFAOYSA-N 0.000 claims description 2
- FWIKWZGVKPJVNJ-UHFFFAOYSA-N 2-(2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-1-phenylethanone Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC(=O)C1=CC=CC=C1 FWIKWZGVKPJVNJ-UHFFFAOYSA-N 0.000 claims description 2
- MKKXDTDAJBNQFR-UHFFFAOYSA-N 2-(4-chlorophenyl)-1-(8-chloro-2-propan-2-yl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)propan-2-ol Chemical compound C1N(C(C)C)CCC2=C1C1=CC(Cl)=CC=C1N2CC(C)(O)C1=CC=C(Cl)C=C1 MKKXDTDAJBNQFR-UHFFFAOYSA-N 0.000 claims description 2
- VPYSJGVLDQLIDR-UHFFFAOYSA-N 2-(8-chloro-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-1-(4-chlorophenyl)ethanone Chemical compound C1N(C)CCC2=C1C1=CC(Cl)=CC=C1N2CC(=O)C1=CC=C(Cl)C=C1 VPYSJGVLDQLIDR-UHFFFAOYSA-N 0.000 claims description 2
- OVFFBWXBLFAZQI-UHFFFAOYSA-N 2-(8-chloro-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-1-(4-fluorophenyl)ethanone Chemical compound C1N(C)CCC2=C1C1=CC(Cl)=CC=C1N2CC(=O)C1=CC=C(F)C=C1 OVFFBWXBLFAZQI-UHFFFAOYSA-N 0.000 claims description 2
- KZSRTBKZNFOLNX-UHFFFAOYSA-N 2-(8-chloro-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-1-cyclobutyl-1-(4-fluorophenyl)ethanol Chemical compound C1N(C)CCC2=C1C1=CC(Cl)=CC=C1N2CC(O)(C=1C=CC(F)=CC=1)C1CCC1 KZSRTBKZNFOLNX-UHFFFAOYSA-N 0.000 claims description 2
- ZPVALAHVRBXBDR-UHFFFAOYSA-N 2-(8-chloro-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-1-phenylethanone Chemical compound C1N(C)CCC2=C1C1=CC(Cl)=CC=C1N2CC(=O)C1=CC=CC=C1 ZPVALAHVRBXBDR-UHFFFAOYSA-N 0.000 claims description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 claims description 2
- RWZMVPSBSUJAPW-UHFFFAOYSA-N 3-[5-[2-(2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)ethyl]pyridin-2-yl]propan-1-amine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(CCCN)N=C1 RWZMVPSBSUJAPW-UHFFFAOYSA-N 0.000 claims description 2
- CIFFOIBAEUIEQJ-UHFFFAOYSA-N 3-[8-methyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b]indol-2-yl]propan-1-ol Chemical compound C1=2CCN(CCCO)CC=2C2=CC(C)=CC=C2N1CCC1=CC=C(C)N=C1 CIFFOIBAEUIEQJ-UHFFFAOYSA-N 0.000 claims description 2
- MZWRHCBZOUSXRZ-UHFFFAOYSA-N 3-[8-methyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b]indol-2-yl]propanenitrile Chemical compound C1=2CCN(CCC#N)CC=2C2=CC(C)=CC=C2N1CCC1=CC=C(C)N=C1 MZWRHCBZOUSXRZ-UHFFFAOYSA-N 0.000 claims description 2
- XBVOPMXREOSTGO-UHFFFAOYSA-N 4-[8-methyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b]indol-2-yl]butan-1-ol Chemical compound C1=2CCN(CCCCO)CC=2C2=CC(C)=CC=C2N1CCC1=CC=C(C)N=C1 XBVOPMXREOSTGO-UHFFFAOYSA-N 0.000 claims description 2
- FJLRAIYQDBDRLE-UHFFFAOYSA-N 8-chloro-2,3-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)C(C)CC2=C1C1=CC(Cl)=CC=C1N2CCC1=CC=C(C)N=C1 FJLRAIYQDBDRLE-UHFFFAOYSA-N 0.000 claims description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000004442 acylamino group Chemical group 0.000 claims description 2
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 2
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 125000005102 carbonylalkoxy group Chemical group 0.000 claims description 2
- 125000005589 carbonylalkylenealkoxy group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 230000019771 cognition Effects 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000004001 thioalkyl group Chemical group 0.000 claims description 2
- 150000003573 thiols Chemical class 0.000 claims description 2
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- WMQWGFBKVULIPU-HSZRJFAPSA-N (2s)-1-(2,8-dimethyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-2-(4-fluorophenyl)butan-2-ol Chemical compound C1([C@](O)(CN2C3=CC=C(C)C=C3C=3CN(C)CCC=32)CC)=CC=C(F)C=C1 WMQWGFBKVULIPU-HSZRJFAPSA-N 0.000 claims 1
- LMOPRCLIZJULDB-UHFFFAOYSA-N 1-(2-fluorophenyl)hexan-2-ol Chemical compound CCCCC(O)CC1=CC=CC=C1F LMOPRCLIZJULDB-UHFFFAOYSA-N 0.000 claims 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 238000003556 assay Methods 0.000 description 12
- 102000015554 Dopamine receptor Human genes 0.000 description 10
- 108050004812 Dopamine receptor Proteins 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 8
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 8
- 108060003345 Adrenergic Receptor Proteins 0.000 description 6
- 102000017910 Adrenergic receptor Human genes 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- NHBJEVLRXOFTHJ-XMMPIXPASA-N (2s)-1-(8-chloro-2-methyl-3,4-dihydro-1h-pyrido[4,3-b]indol-5-yl)-2-(4-fluorophenyl)hexan-2-ol Chemical compound C1([C@](O)(CN2C3=CC=C(Cl)C=C3C=3CN(C)CCC=32)CCCC)=CC=C(F)C=C1 NHBJEVLRXOFTHJ-XMMPIXPASA-N 0.000 description 1
- GHTZJIVVVQOYLU-UHFFFAOYSA-N 2,3,8-trimethyl-5-[2-[6-(trifluoromethyl)pyridin-3-yl]ethyl]-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)C(C)CC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C(F)(F)F)N=C1 GHTZJIVVVQOYLU-UHFFFAOYSA-N 0.000 description 1
- UFIWAIHZSRQCSQ-UHFFFAOYSA-N 2,4,8-trimethyl-5-[2-[6-(trifluoromethyl)pyridin-3-yl]ethyl]-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound CC1CN(C)CC(C2=CC(C)=CC=C22)=C1N2CCC1=CC=C(C(F)(F)F)N=C1 UFIWAIHZSRQCSQ-UHFFFAOYSA-N 0.000 description 1
- HZJIAQPXOPTQEV-UHFFFAOYSA-N 2,8-dimethyl-5-(2-methyl-2-pyridin-4-ylpropyl)-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC(C)(C)C1=CC=NC=C1 HZJIAQPXOPTQEV-UHFFFAOYSA-N 0.000 description 1
- QTZGWBMTEBWKCY-UHFFFAOYSA-N 2,8-dimethyl-5-(2-pyridin-4-ylpropyl)-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1=2CCN(C)CC=2C2=CC(C)=CC=C2N1CC(C)C1=CC=NC=C1 QTZGWBMTEBWKCY-UHFFFAOYSA-N 0.000 description 1
- VGEXGNXCTMOZOI-UHFFFAOYSA-N 2,8-dimethyl-5-[(1-pyridin-4-ylcyclopropyl)methyl]-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CC1(C=2C=CN=CC=2)CC1 VGEXGNXCTMOZOI-UHFFFAOYSA-N 0.000 description 1
- 108091005435 5-HT6 receptors Proteins 0.000 description 1
- YQTFPJLMJDAXTM-UHFFFAOYSA-N 8-methyl-5-[2-(6-methylpyridin-3-yl)ethyl]-2-(2,2,2-trifluoroethyl)-3,4-dihydro-1h-pyrido[4,3-b]indole Chemical compound C1=2CCN(CC(F)(F)F)CC=2C2=CC(C)=CC=C2N1CCC1=CC=C(C)N=C1 YQTFPJLMJDAXTM-UHFFFAOYSA-N 0.000 description 1
- XUICNFHKQXZCDS-UHFFFAOYSA-N 8-methyl-5-[2-[6-(trifluoromethyl)pyridin-3-yl]ethyl]-1,2,3,4-tetrahydropyrido[4,3-b]indole Chemical compound C1=2CCNCC=2C2=CC(C)=CC=C2N1CCC1=CC=C(C(F)(F)F)N=C1 XUICNFHKQXZCDS-UHFFFAOYSA-N 0.000 description 1
- XHUWROVEEFXLID-UHFFFAOYSA-N CCC(CC)CCC#N Chemical compound CCC(CC)CCC#N XHUWROVEEFXLID-UHFFFAOYSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1136MU2009 | 2009-04-29 | ||
| IN1136/MUM/2009 | 2009-04-29 | ||
| US18126209P | 2009-05-26 | 2009-05-26 | |
| US61/181,262 | 2009-05-26 | ||
| PCT/US2010/033053 WO2010127177A1 (en) | 2009-04-29 | 2010-04-29 | Pyrido [4,3-b] indoles and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012525430A JP2012525430A (ja) | 2012-10-22 |
| JP2012525430A5 true JP2012525430A5 (OSRAM) | 2013-06-27 |
| JP5711725B2 JP5711725B2 (ja) | 2015-05-07 |
Family
ID=43032567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012508751A Expired - Fee Related JP5711725B2 (ja) | 2009-04-29 | 2010-04-29 | ピリド［４，３−ｂ］インドールおよびその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9255094B2 (OSRAM) |
| EP (1) | EP2424364A4 (OSRAM) |
| JP (1) | JP5711725B2 (OSRAM) |
| CN (1) | CN102480955B (OSRAM) |
| AU (1) | AU2010242910B2 (OSRAM) |
| BR (1) | BRPI1006602A2 (OSRAM) |
| CA (1) | CA2760541A1 (OSRAM) |
| WO (1) | WO2010127177A1 (OSRAM) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2007139634A (ru) * | 2007-10-25 | 2009-04-27 | Сергей Олегович Бачурин (RU) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения |
| RU2544856C2 (ru) * | 2008-01-25 | 2015-03-20 | Сергей Олегович Бачурин | НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| CN104387382A (zh) | 2008-03-24 | 2015-03-04 | 梅迪维新技术公司 | 吡啶并[3,4-b]吲哚和应用方法 |
| WO2009120720A1 (en) * | 2008-03-24 | 2009-10-01 | Medivation Technologies,Inc. | Bridged heterocyclic compounds and methods of use |
| US8907097B2 (en) | 2008-10-31 | 2014-12-09 | Medivation Technologies, Inc. | Pyrido[4,3-b]indoles containing rigid moieties |
| AU2009308708B2 (en) | 2008-10-31 | 2015-11-19 | Medivation Technologies, Inc. | Azepino [4, 5-b] indoles and methods of use |
| RU2011137419A (ru) | 2009-02-11 | 2013-03-20 | Суновион Фармасьютикалз Инк. | Обратные агонисты и антагонисты гистамина н3 и способы их применения |
| EP2424366B1 (en) * | 2009-04-29 | 2016-02-17 | Medivation Technologies, Inc. | Pyrido [4, 3-b]indoles and methods of use |
| EP2424364A4 (en) | 2009-04-29 | 2012-12-19 | Medivation Technologies Inc | PYRIDO [4.3-B] INDOLES AND METHODS OF USE |
| WO2011038163A1 (en) | 2009-09-23 | 2011-03-31 | Medivation Technologies, Inc. | Pyrido[3,4-b]indoles and methods of use |
| US8859561B2 (en) | 2009-09-23 | 2014-10-14 | Medivation Technologies, Inc. | Pyrido[4,3-b]indoles and methods of use |
| JP5869484B2 (ja) | 2009-09-23 | 2016-02-24 | メディベイション テクノロジーズ， インコーポレイテッド | 架橋複素環化合物およびその使用 |
| US9034865B2 (en) | 2010-02-18 | 2015-05-19 | Medivation Technologies, Inc. | Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
| US9040519B2 (en) | 2010-02-18 | 2015-05-26 | Medivation Technologies, Inc. | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
| WO2011103460A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use |
| US9187471B2 (en) | 2010-02-19 | 2015-11-17 | Medivation Technologies, Inc. | Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use |
| CA2816088A1 (en) * | 2010-10-28 | 2012-05-03 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| WO2012112961A1 (en) | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | Compounds and methods of treating hypertension |
| US20140155384A1 (en) | 2011-02-18 | 2014-06-05 | Medivation Technologies, Inc. | Compounds and methods of treating diabetes |
| BR112013021126A2 (pt) | 2011-02-18 | 2019-09-24 | Medivation Technologies Inc | método para reduzir a pressão sanguínea, método para aumentar o fluxo sanguíneo renal ou diminuir a reabsorção de sódio, método para tratar uma doença, kit, composto e composição farmacêutica |
| US9035056B2 (en) | 2011-02-18 | 2015-05-19 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| RU2490268C2 (ru) * | 2011-11-10 | 2013-08-20 | Федеральное Государственное Бюджетное Учреждение Науки Институт Физиологически Активных Веществ Российской Академии Наук (Ифав Ран) | ХЛОРГИДРАТЫ ФТОРСОДЕРЖАЩИХ ЗАМЕЩЕННЫХ 5-[2-(ПИРИД-3-ИЛ)-ЭТИЛ]-2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛОВ, В КАЧЕСТВЕ СРЕДСТВ СНИЖЕНИЯ НЕКОНТРОЛИРУЕМОЙ АГРЕГАЦИИ БЕЛКОВ В НЕРВНОЙ СИСТЕМЕ, ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ИХ ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| CN103974956B (zh) * | 2011-11-29 | 2016-07-06 | 南京奥昭生物科技有限公司 | 作为hdac6抑制剂和用作抗肿瘤剂的杂环酰胺化合物 |
| US20150315188A1 (en) * | 2012-08-22 | 2015-11-05 | Medivation Technologies, Inc. | Compounds and methods for treatment of hypertension |
| WO2014031170A1 (en) * | 2012-08-22 | 2014-02-27 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| US10092550B2 (en) | 2014-10-21 | 2018-10-09 | Ions Pharmaceutical S.À R.L. | Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof |
| US9907786B2 (en) | 2014-10-21 | 2018-03-06 | Ions Pharmaceutical S.À R.L. | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof |
| US12129265B2 (en) | 2020-07-21 | 2024-10-29 | Ankh Life Sciences Limited | Therapeutic agents and uses thereof |
| KR20230171634A (ko) * | 2022-06-14 | 2023-12-21 | 주식회사 레고켐 바이오사이언스 | 엑토뉴클레오티드 피로포스파타아제 포스포디에스터라아제-1 저해 화합물 및 이를 함유하는 약제학적 조성물 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3409628A (en) | 1966-05-12 | 1968-11-05 | Hoffmann La Roche | 5-(3-pyridylethyl)pyridoindole derivatives |
| US3484449A (en) | 1966-05-12 | 1969-12-16 | Hoffmann La Roche | Certain substituted phenyl amino-ethylpyridine intermediates |
| US3502688A (en) | 1968-09-10 | 1970-03-24 | Hoffmann La Roche | 5-(4-pyridylethyl)-pyridoindole derivatives |
| US3646045A (en) | 1968-09-10 | 1972-02-29 | Hoffmann La Roche | Intermediates for 5-(4-pyridylethyl)-pyridoindole derivatives |
| JPS5143863B2 (OSRAM) | 1973-06-18 | 1976-11-25 | ||
| US4754038A (en) | 1987-02-26 | 1988-06-28 | American Home Products Corporation | Carboline histamine H1 antagonists |
| AU631131B2 (en) | 1988-08-02 | 1992-11-19 | Glaxo Group Limited | Lactam derivatives |
| RU2140417C1 (ru) | 1995-10-17 | 1999-10-27 | Институт физиологически активных веществ РАН | Производные гидрированных пиридо(4,3-b)индолов, способы их получения, фармацевтическая композиция и способ лечения |
| RU2106864C1 (ru) | 1995-10-23 | 1998-03-20 | Николай Серафимович Зефиров | Средство для лечения болезни альцгеймера |
| DE10030375A1 (de) | 2000-06-21 | 2002-01-03 | Bayer Ag | Verwendung von MTP-Inhibitoren zur Senkung von ppTRL |
| WO2003014118A1 (en) * | 2001-08-08 | 2003-02-20 | Pharmacia & Upjohn Company | THERAPEUTIC 1H-PYRIDO[4,3-b]INDOLES |
| RU2283108C2 (ru) | 2003-12-08 | 2006-09-10 | Сергей Олегович Бачурин | ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| AP2334A (en) | 2004-12-17 | 2011-12-06 | Glenmark Pharmaceuticals Sa | Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders. |
| JP2009502959A (ja) * | 2005-07-28 | 2009-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | セロトニン受容体アゴニストおよびアンタゴニストとしての置換テトラヒドロ−１ｈ−ピリド［４，３，ｂ］インドール |
| EP1937263A2 (en) | 2005-10-04 | 2008-07-02 | Medivation, Inc. | Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease |
| RU2338537C2 (ru) * | 2006-01-25 | 2008-11-20 | Сергей Олегович Бачурин | СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| WO2008036400A2 (en) | 2006-09-20 | 2008-03-27 | Medivation Neurology, Inc. | Hydrogenated pyrido [4,3-b] indoles such as dimebon for treating canine cognitive dysfunction syndrome |
| AU2007297539A1 (en) | 2006-09-20 | 2008-03-27 | Medivation Neurology, Inc. | Methods and compositions for treating amyotrophic lateral sclerosis (ALS) |
| BRPI0718437A2 (pt) * | 2006-10-27 | 2013-11-19 | Medivation Neurology Inc | Métodos e terapias de combinação para tratar a doença de alzheimer usando, entre outros, dimebon e dolepezil |
| RU2329044C1 (ru) | 2006-11-16 | 2008-07-20 | Андрей Александрович Иващенко | Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство |
| RU2334514C1 (ru) | 2006-12-01 | 2008-09-27 | Институт физиологически активных веществ Российской Академии наук | СРЕДСТВО ДЛЯ УЛУЧШЕНИЯ КОГНИТИВНЫХ ФУНКЦИЙ И ПАМЯТИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО (4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| RU2340342C2 (ru) | 2006-12-07 | 2008-12-10 | Сергей Олегович Бачурин | СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И ХРОНИЧЕСКИХ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ, В ТОМ ЧИСЛЕ ИНСУЛЬТА, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО[4,3-b]ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| RU2338745C1 (ru) | 2007-03-21 | 2008-11-20 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| RU2339637C1 (ru) | 2007-04-05 | 2008-11-27 | Андрей Александрович Иващенко | Блокаторы гистаминного рецептора для фармацевтических композиций, обладающих противоаллергическим и аутоиммунным действием |
| WO2008123796A2 (ru) * | 2007-04-05 | 2008-10-16 | Alla Chem, Llc | Замещенные 2,3,4,5-tetpaгидpo-1h-пиpидo[4,3-b]иhдoлы, способ их получения и применения |
| WO2008147551A1 (en) | 2007-05-25 | 2008-12-04 | Medivation Nuerology, Inc. | Methods and compositions for stimulating cells |
| RU2338533C1 (ru) | 2007-06-28 | 2008-11-20 | Сергей Олегович Бачурин | СРЕДСТВО, ОБЛАДАЮЩЕЕ АНКСИОЛИТИЧЕСКИМ ДЕЙСТВИЕМ, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| CA2719824A1 (en) * | 2007-08-01 | 2009-02-05 | Medivation Neurology, Inc. | Methods and compositions for treating schizophrenia using antipsychotic combination therapy |
| US20090221627A1 (en) * | 2007-09-20 | 2009-09-03 | Alexey Aksinenko | Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use |
| WO2009039420A1 (en) | 2007-09-21 | 2009-03-26 | Medivation Neurology, Inc. | Methods and compositions for treating neuronal death mediated ocular diseases |
| RU2007139634A (ru) * | 2007-10-25 | 2009-04-27 | Сергей Олегович Бачурин (RU) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения |
| JP2011507835A (ja) | 2007-12-21 | 2011-03-10 | アンドレイ・アレクサンドロビッチ・イワシェンコ | α−アドレナリン受容体、ドーパミン、ヒスタミン、イミダゾリン及びセロトニン受容体のリガンド並びにその使用 |
| RU2544856C2 (ru) | 2008-01-25 | 2015-03-20 | Сергей Олегович Бачурин | НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| WO2009111540A1 (en) | 2008-03-04 | 2009-09-11 | Medivation Neurology, Inc. | Methods for preparing pyridylethyl-substituted carbolines |
| WO2009120720A1 (en) | 2008-03-24 | 2009-10-01 | Medivation Technologies,Inc. | Bridged heterocyclic compounds and methods of use |
| CN104387382A (zh) | 2008-03-24 | 2015-03-04 | 梅迪维新技术公司 | 吡啶并[3,4-b]吲哚和应用方法 |
| WO2009135091A1 (en) | 2008-04-30 | 2009-11-05 | Medivation Technologies, Inc. | Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions |
| US20100029706A1 (en) | 2008-07-30 | 2010-02-04 | Edison Parmaceuticals, Inc. a Delaware Corporation | HYDROGENATED PYRIDO[4,3-b]INDOLES FOR THE TREATMENT OF OXIDATIVE STRESS |
| US9625475B2 (en) | 2008-09-29 | 2017-04-18 | Abbvie Inc. | Indole and indoline derivatives and methods of use thereof |
| CA2737031A1 (en) | 2008-09-29 | 2010-04-01 | Abbott Laboratories | Indole and indoline derivatives and methods of use thereof |
| AU2009308708B2 (en) | 2008-10-31 | 2015-11-19 | Medivation Technologies, Inc. | Azepino [4, 5-b] indoles and methods of use |
| US8907097B2 (en) | 2008-10-31 | 2014-12-09 | Medivation Technologies, Inc. | Pyrido[4,3-b]indoles containing rigid moieties |
| US9962368B2 (en) | 2009-01-09 | 2018-05-08 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| AU2010203356B2 (en) | 2009-01-09 | 2015-11-26 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| US8362277B2 (en) | 2009-01-09 | 2013-01-29 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| EP2424364A4 (en) | 2009-04-29 | 2012-12-19 | Medivation Technologies Inc | PYRIDO [4.3-B] INDOLES AND METHODS OF USE |
| EP2424366B1 (en) | 2009-04-29 | 2016-02-17 | Medivation Technologies, Inc. | Pyrido [4, 3-b]indoles and methods of use |
| WO2011008312A2 (en) | 2009-07-14 | 2011-01-20 | Abbott Laboratories | Indole and indoline derivatives and methods of use thereof |
| WO2011014695A1 (en) | 2009-07-29 | 2011-02-03 | Medivation Technologies, Inc. | New 2,3,4,5-tetrahydro-1h-pyrido[4,3-b] indoles and methods of use |
| JP5791611B2 (ja) | 2009-09-23 | 2015-10-07 | メディベイション テクノロジーズ， インコーポレイテッド | ピリド［３，４−ｂ］インドールおよび使用方法 |
| JP5869484B2 (ja) | 2009-09-23 | 2016-02-24 | メディベイション テクノロジーズ， インコーポレイテッド | 架橋複素環化合物およびその使用 |
| WO2011038163A1 (en) | 2009-09-23 | 2011-03-31 | Medivation Technologies, Inc. | Pyrido[3,4-b]indoles and methods of use |
| US8859561B2 (en) | 2009-09-23 | 2014-10-14 | Medivation Technologies, Inc. | Pyrido[4,3-b]indoles and methods of use |
| US20130172320A1 (en) | 2010-02-18 | 2013-07-04 | Sarvajit Chakravarty | Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use |
| WO2011103460A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use |
| US9034865B2 (en) | 2010-02-18 | 2015-05-19 | Medivation Technologies, Inc. | Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
| US9040519B2 (en) | 2010-02-18 | 2015-05-26 | Medivation Technologies, Inc. | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
| WO2011103448A1 (en) | 2010-02-19 | 2011-08-25 | Medivation Technologies, Inc. | Methods and compositions for treating psychotic disorders using antipsychotic combination therapy |
| US9187471B2 (en) | 2010-02-19 | 2015-11-17 | Medivation Technologies, Inc. | Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use |
| AU2011274787B2 (en) | 2010-07-07 | 2016-06-16 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| BR112013021126A2 (pt) | 2011-02-18 | 2019-09-24 | Medivation Technologies Inc | método para reduzir a pressão sanguínea, método para aumentar o fluxo sanguíneo renal ou diminuir a reabsorção de sódio, método para tratar uma doença, kit, composto e composição farmacêutica |
| WO2012112961A1 (en) | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | Compounds and methods of treating hypertension |
| US9035056B2 (en) | 2011-02-18 | 2015-05-19 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| US20140155384A1 (en) | 2011-02-18 | 2014-06-05 | Medivation Technologies, Inc. | Compounds and methods of treating diabetes |
| US20150315188A1 (en) | 2012-08-22 | 2015-11-05 | Medivation Technologies, Inc. | Compounds and methods for treatment of hypertension |
| WO2014031170A1 (en) | 2012-08-22 | 2014-02-27 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| JP6231566B2 (ja) | 2012-08-24 | 2017-11-15 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 神経新生促進化合物 |
-
2010
- 2010-04-29 EP EP10770380A patent/EP2424364A4/en not_active Withdrawn
- 2010-04-29 JP JP2012508751A patent/JP5711725B2/ja not_active Expired - Fee Related
- 2010-04-29 AU AU2010242910A patent/AU2010242910B2/en not_active Ceased
- 2010-04-29 CA CA2760541A patent/CA2760541A1/en not_active Abandoned
- 2010-04-29 BR BRPI1006602A patent/BRPI1006602A2/pt not_active IP Right Cessation
- 2010-04-29 CN CN201080028795.7A patent/CN102480955B/zh not_active Expired - Fee Related
- 2010-04-29 WO PCT/US2010/033053 patent/WO2010127177A1/en not_active Ceased
- 2010-04-29 US US13/318,123 patent/US9255094B2/en not_active Expired - Fee Related
-
2013
- 2013-03-08 US US13/791,796 patent/US20130190328A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2417994C2 (ru) | Производные пиразина, полезные в качестве антагонистов аденозинового рецептора | |
| JP2022544946A5 (OSRAM) | ||
| UY28970A1 (es) | Compuestos moduladores de la actividad de c-kit y usos de los mismos | |
| JP2016536364A5 (OSRAM) | ||
| JP2019509319A5 (OSRAM) | ||
| WO2007013896A3 (en) | Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors | |
| JP2016520118A5 (OSRAM) | ||
| NZ597647A (en) | Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors | |
| TN2011000220A1 (en) | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | |
| WO2010068483A3 (en) | Mlk inhibitors and methods of use | |
| MA30076B1 (fr) | Carbonylaminopyrrolopyrazoles servant de puissants inhibiteurs de kinases. | |
| JP2011507854A5 (OSRAM) | ||
| PE20090493A1 (es) | DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
| JP2013505948A5 (OSRAM) | ||
| MX344733B (es) | Composiciones y metodos de uso de la quinasa-1 similar al receptor de la activina. | |
| SI3009431T1 (en) | 2- (2,4,5-substituted-anilino) pyrimidine derivatives, as EGFR modulators useful for the treatment of cancer | |
| EA201291236A1 (ru) | Азотные гетероциклические соединения, применимые в качестве ингибиторов pde10 | |
| NZ600801A (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
| JP2016537384A5 (OSRAM) | ||
| PH12012500809A1 (en) | Methods and compositions for treating cancer | |
| PE20150723A1 (es) | Compuestos antiviricos para el vsr | |
| MX2009004807A (es) | Aminopiridinas y aminopirimidinas utiles como inhibidores de proteina cinasa. | |
| SI2509974T1 (en) | Pyrazoles derivatives modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer | |
| WO2009023844A3 (en) | 3' substituted compounds having 5-ht6 receptor affinity | |
| WO2013056070A3 (en) | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases |